Abiraterone acetate in the treatment of patients with metastatic prostate cancer by unknown
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ABSTRACT
For a long time, systemic treatment of patients diagnosed with metastatic castration-resistant prostate cancer 
(mCRPC) has been based solely on chemotherapy (docetaxel). The introduction of novel endocrine agents has 
significantly improved outcomes of mCRPC patients. Till date, abirateron acetate is the only drug with confirmed 
activity (significant improvement in overall survival) in both clinical settings: castration resistance (pre or post 
chemotherapy) and castration sensitivity. The article is aimed to summarize current knowledge on the place and 
role of abiraterone acetate in palliative systemic treatment of metastatic prostate cancer patients.
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Introduction
The treatment of patients with disseminated castra-
tion-resistant prostate cancer (CRPC) has undergone 
a huge evolution over the last decade. In 2004, based 
on the results of the TAX327 study, docetaxel was 
registered, which significantly improved the prognosis 
of patients with metastatic CRPC compared to the 
current standard of chemotherapy — mitoxantrone, 
reducing the relative risk of death by 21% [1]. In the 
years following the introduction of docetaxel into clini-
cal practice, numerous clinical trials have been initiated 
on new strategies of systemic treatment for patients 
with CRPC. These studies have been conducted in 
two main directions: (i) increasing the effectiveness of 
docetaxel-based chemotherapy by combining it with 
other drugs and (ii) developing active treatment op-
tions for patients after chemotherapy failure. In order 
to improve the effectiveness of docetaxel in the treat-
ment of CRPC patients, attempts were made to combine 
this drug with bevacizumab, aflibercept, dasatinib (Src 
kinase inhibitor), zibotentan (ETA receptor inhibitor), 
or calcitriol [2–6]. Apart from a marked increase in treat-
ment-related toxicity, none of above studies has shown 
significant improvement in prognosis. However, success-
ful research on new strategies for systemic treatment of 
CRPC patients following the failure of docetaxel-based 
chemotherapy has led to the registration of several new 
drugs — hormone (abiraterone acetate — 2011 and en-
zalutamid — 2012), chemotherapy (cabazitaxel — 2010), 
and radioisotope (alpharadin — 2013). 
Significant improvement of systemic treatment 
effectiveness for prostate cancer patients in the follow-
ing years has been reported in patients with metastatic 
CRPC not previously treated with chemotherapy as 
well as in patients with primary disseminated cancer. As 
a result of performed studies abiraterone and enzaluta-
mid were registered for the treatment of patients with 
metastatic CRPC, who had not previously undergone 
chemotherapy. In contrast, docetaxel, in combination 
with pharmacological castration, has become a stand-
ard treatment for patients with primary disseminated 
prostate cancer. 
Among new systemic therapies registered for treat-
ment of prostate cancer patients, to date only abira-
terone acetate has obtained reimbursement status in 
Poland under the therapeutic drug program. This drug 
is currently the only hormone available with clearly 
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proven activity at various stages of metastatic prostate 
cancer. The aim of this article is to summarise current 
evidence on the role and place of abiraterone acetate in 
the treatment of patients with advanced prostate cancer. 
Mechanism of action of abiraterone 
acetate 
Abiraterone is a selective inhibitor of cytochrome 
P450 c17 (CYP17), an enzyme having 17a-hydroxylase 
and C17,20-lyase activity. CYP17 is essential for the 
biosynthesis of androgens in the testes, adrenal glands, 
and prostate cancer cells. Abiraterone inhibits androgen 
biosynthesis at the stage of pregnenolone and proges-
terone metabolism and leads to decrease in synthesis of 
testosterone and thus 5-a-dihydrotestosterone inducing 
proliferation of prostate cells. Abiraterone reduces 
testosterone and other androgen serum levels more 
than LHRH analogues or orchidectomy. Thus, the use 
of this drug by definition overcomes the resistance of 
prostate cancer cells to androgen deprivation. As a re-
sult of inhibition of CYP17 activity and reduction of 
glucocorticoid synthesis, ACTH level increases, result-
ing in increased synthesis of mineralocorticosteroids in 
adrenal glands. The excess of mineralocorticosteroids 
leads in turn to abiraterone-typical side effects — hy-
pertension, hypokalaemia, and fluid retention. The use 
of glucocorticosteroids [prednisone 10 mg/d (divided 
dose)] reduces ACTH concentration and prevents the 
onset of the aforementioned undesirable effects. The 
mechanism of action of abiraterone is similar to that of 
ketoconazole, which was sometimes used in subsequent 
hormonal lines. However, the use of ketoconazole in the 
treatment of CRPC was characterised by low clinical 
activity with relatively high toxicity [7, 8].
Abiraterone acetate in the treatment  
of CRPC after chemotherapy
In their first phase, the studies on the role and place 
of abiraterone in the treatment of advanced prostate 
cancer patients were focused on the patient population 
after failure of docetaxel-based chemotherapy.
The phase III COU-AA-301 study involved 1195 pa-
tients with metastatic CRPC, who developed disease 
progression (biochemical or radiological) during or after 
discontinuation of docetaxel-based chemotherapy. Pa-
tients in ECOG performance status (PS) 0–2 and under 
continuous pharmacological castration were randomly 
assigned (2:1) to either the experimental arm [abirater-
one 1000 mg/d + prednisone 10 mg/d (divided dose)] 
or the control group [placebo + prednisone 10 mg/d 
(divided dose)]. The study primary endpoint was overall 
survival (OS). The use of abiraterone was associated 
with a significant reduction in relative risk of death by 
26% (HR = 0.74; 95% CI 0.64–0.86), and median OS 
was 15.8 months and 11.2 months in the abiraterone and 
placebo group, respectively. 
Abiraterone significantly reduced the relative risk 
of biochemical progression by 42% (p < 0.001) and 
radiological progression by 33% (p < 0.001), also in-
creasing the radiological response rate in patients with 
measurable lesions from 3% to 14% and biochemical 
lesions from 6% to 29% [9, 10]. 
Based on the FACT-P (Functional Assessment 
of Cancer Therapy — Prostate) questionnaire, the 
COU-AA-301 study demonstrated the beneficial effect 
of abiraterone on patients’ quality of life both in terms of 
improvement of initially reduced parameters as well as 
delaying significant deterioration in quality of life [11].
Abiraterone acetate in the treatment  
of CRPC before chemotherapy
The natural consequence of demonstration of abira-
terone activity in the treatment of patients after chemo-
therapy failure was a study evaluating the efficacy of this 
drug in a population of CRPC patients not previously 
receiving docetaxel. The COU-AA-302 study involved 
1088 asymptomatic or oligosymptomatic patients with 
metastatic CRPC, in ECOG PS 0–1, without systemic 
metastasis. Patients were randomly assigned (1:1) to 
a group receiving either abiraterone + prednisone or 
placebo + prednisone. The first published study analysis 
demonstrated a significant increase in median radio-
graphic progression-free survival (rPFS) — 16.5 months 
vs. 8.3 months in the abiraterone and placebo arm, 
respectively, which transferred into a reduction in risk 
of progression or death by 47% in the abiraterone 
arm (HR = 0.53; 95% CI 0.45–0.62) [12]. The use of 
abiraterone significantly reduced the risk of PS (18%) 
and quality of life (22%) deterioration as well as occur-
rence of pain requiring opioids (32%), prolonging the 
time to chemotherapy initiation (from 16.8 months to 
25.2 months). Abiraterone significantly increased the 
percentage of patients with biochemical (62% vs. 24%) 
and radiological response (36% vs. 16%). Due to the 
fact that 44% of patients (n = 238) in the placebo arm 
received abiraterone after progression of disease, the 
final assessment of the effect of the drug on patients’ 
overall survival required the use of the iterative param-
eter estimation (IPE) method. The final survival analysis 
was performed after a median follow-up of 49.2 months 
and 96% of expected survival events (741 deaths) [13]. 
Taking into account the impact of cross-over procedure, 
the use of abiraterone was associated with a significant 
decrease (by 19%) in relative risk of death in patients 
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with metastatic CRPC (HR = 0.81, 95% CI 0.70–0.93). 
OS median was 34.7 months and 30.3 months in abira-
terone and placebo group, respectively.
The use of abiraterone acetate in patients with 
metastatic CRPC, who had not previously undergone 
chemotherapy, was associated with a typical and ac-
ceptable toxicity profile and a positive effect on their 
quality of life [14].
In a retrospective analysis of the COU-AA-301 study, 
the greatest benefit of abiraterone for overall survival 
was observed in asymptomatic patients in very good 
performance status. 
Abiraterone acetate in disseminated 
castration-sensitive prostate cancer
The CHAARTED and STAMPED studies have 
shown a significant improvement in prognosis of patients 
with primary disseminated prostate cancer as a result 
of hormone therapy and chemotherapy administered 
together (androgen deprivation in combination with 
six docetaxel courses) compared to pharmacological 
castration alone [15–17]. The combination of hormone 
therapy and chemotherapy is now recognised as standard 
practice in previously untreated patients with extensive 
metastatic cancer, at the stage of potential sensitivity 
to castration.
In June 2017, the results of the phase III LATI-
TUDE and STAMPEDE studies evaluating the clinical 
effect of abiraterone acetate (+ prednisone) in combi-
nation with pharmacological castration in patients with 
primary disseminated prostate cancer were published 
[17, 18]. The LATITUDE study included 1199 patients 
in ECOG PS 0–2 with newly diagnosed (≤ 3 months) 
generalised prostate cancer without the features of 
neuroendocrine or microcellular differentiation. In all 
patients, it was necessary to acknowledge the spread 
of tumour process and to demonstrate at least two of 
three high-risk criteria: (i) Gleason score ≥ 8, (ii) at least 
three metastatic bone lesions, (iii) measurable internal 
metastasis. Patients were randomly assigned to receive 
abiraterone in combination with androgen deprivation 
or to the arm receiving placebo together with androgen 
deprivation. First interim analysis of primary endpoints 
showed a significant reduction in relative risk of death 
by 38% and radiological progression by 53%. The 
three-year survival rate was 66% vs. 49% (HR = 0.65; 
95% CI 0.51–0.76) and median rPFS 33.0 vs. 14.8 months 
(HR = 0.47; 95% CI 0.39–0.55) in the abiraterone and 
placebo arm, respectively [18]. 
In the multi-arm, multi-stage STAMPEDE study, the 
data from 1917 patients were analysed, assigned (1:1) 
to an experimental [Androgen-Deprivation Therapy 
(ADT) + abiraterone for two years] or control arm 
(ADT alone). Unlike LATITUTE, to the STAMPEDE 
study not only were previously untreated patients in 
stage IV qualified, but also patients in stage III or stage 
II with coexisting risk factors and patients with recur-
rence of disease after surgery or radiotherapy. The 
combination of abiraterone with ADT was associated 
with a significant reduction in relative risk of death in 
the general patient population by 37% (HR = 0.67; 
95% CI 0.52–0.76) with an increase in the three-year 
survival rate from 76% (ADT) up to 83% (abirater-
one + ADT). The three-year treatment failure-free 
survival rate was 75% (abiraterone + ADT) and 45% 
(ADT), which translated into a 70% reduction in the risk 
of treatment failure (HR = 0.29; 95% CI 0.25–0.34). In 
turn, the risk of radiological progression was reduced 
in the abiraterone receiving arm by 60% (p < 0.001). 
Retrospective subgroup analyses for overall survival 
suggest no superiority of combination therapy com-
pared to androgen deprivation alone in patients at the 
age of ≥ 70 years despite a clear reduction in the risk of 
treatment failure [19]. 
The safety profile of combination therapy with abi-
raterone + ADT was similar in the LATITUDE and 
STAMPEDE studies, with clearly higher proportions 
of adverse events in 3–4 degrees according to CTCAE 
in the experimental arms.
Summary
The COU-AA-301 and COU-AA-302 studies, 
as well as the recently published LATITUDE and 
STAMPEDE studies, clearly point to the significant 
role of abiraterone acetate in the armamentarium of 
drugs used for treatment of patients with disseminated 
prostate cancer. With regard to neoplastic process at 
sensitivity-to-castration stage, abiraterone dramatically 
increases the activity of classical castration-based hor-
mone therapy. At the time being it is difficult to judge 
which strategy — chemotherapy together with hormone 
therapy (ADT + docetaxel) or combination hormone 
therapy (ADT + abiraterone) — is a better therapeutic 
option. Most likely, due to differences in safety profiles 
(18 weeks of chemotherapy versus at least 24 months of 
therapy with abiraterone), different treatment strategies 
will be used for different patients. The comparison of 
ADT + abiraterone with ADT + docetaxel, expected 
within the multi-arm STAMPEDE study, should provide 
extremely interesting information. 
However, there is no doubt that at present the key 
role of abiraterone is the treatment of patients with 
disseminated prostate cancer at the stage of castration 
resistance. In the vast majority of cases, progression 
of disease with post-castration testosterone levels 
results from androgen receptor stimulation by andro-
gens produced in tissues being out of control by the 
hypothalamic-pituitary system. Abiraterone system-
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atically inhibits androgen biosynthesis, thus completely 
blocking the possibility of stimulating the androgen 
receptor through this group of sex hormones, and the 
progression of disease during treatment with abira-
terone is a typical hormonal resistance phenomenon. 
Considering potential abiraterone use both before and 
after docetaxel-based chemotherapy, the key issue in 
clinical practice is which strategy — chemotherapy or 
hormone therapy — should be used first. Abiraterone 
appears to be the first-line option in asymptomatic or 
oligosymptomatic patients with metastatic CRPC in 
good performance status (ECOG 0–1) without sys-
temic metastases. In turn, docetaxel should be used in 
the first-line setting in patients with metastatic CRPC, 
who experience metastases in internal organs or severe 
disease-related symptoms. Scores of Gleason’s scoring 
system for degree of malignancy < 8, which is postulated 
by some researchers as a potential indication for use of 
abiraterone in first-line treatment of CRPC patients, 
should not be used in the decision-making process. This 
is due to the fact that to date no correlation between 
the degree of malignancy and efficacy of abiraterone 
has been confirmed [20]. 
In clinical practice, however, one should always 
pay attention to the nature of disease progression after 
failure of new-generation hormone drugs (abiraterone, 
enzalutamide). As a consequence of complete blockade 
of hormone-dependent signal transduction, these drugs 
force the activation of numerous adaptive mechanisms 
in tumour cells, including loss of adenocarcinoma phe-
notype. The appearance of organ metastases, change 
of bone metastases nature from osteosclerotic to 
osteolytic, absent/slight biochemical progression with 
marked imaging/clinical progression, and elevated carci-
noembryonic antigen (CEA) level, may be indicative of 
neuroendocrine differentiation of cancer cells [21]. Since 
the new-generation hormone drugs are commonly used, 
the phenomenon of neuroendocrine differentiation is 
increasingly observed; such clinical situations require 
the use of platinum-containing chemotherapy regimens 
(e.g. docetaxel + carboplatin) [22]. 
The introduction of new-generation hormone 
drugs has greatly improved the prognosis of patients 
with disseminated castration-resistant prostate cancer. 
However, there is no doubt that the place of these drugs 
in clinical practice will continue to evolve, and the best 
proof of it is the possibility of using abiraterone still at 
the stage of castration-sensitive cancer. 
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